Immune memory in mild COVID-19 patients and unexposed donors from India reveals persistent T cell responses after SARS-CoV-2 infection.
Immune memory in mild COVID-19 patients and unexposed donors from India reveals persistent T cell responses after SARS-CoV-2 infection.
复制标题
来自印度的轻度 COVID-19 患者和未暴露的捐赠者的免疫记忆揭示了 SARS-CoV-2 感染后持续的 T 细胞反应。
DOI：
10.1101/2020.11.16.20232967
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Gupta,Nimesh
中科院分区：
文献类型：
--
作者：
Ansari,Asgar;Arya,Rakesh;Sachan,Shilpa;Jha,SomeshwarNath;Kalia,Anurag;Lall,Anupam;Sette,Alessandro;Grifoni,Alba;Weiskopf,Daniela;Coshic,Poonam;Sharma,Ashok;Gupta,Nimesh
38了解COVID-19大流行在39个不同地理位置产生不同结果的原因，对全球疫苗实施和大流行控制应对至关重要。我们分析了42名未暴露的健康供体和28名轻度COVID-19受试者，他们从SARS-CoV-2特异性免疫记忆恢复到41至5个月。使用42个HLA II类预测肽库，我们在约66%的未暴露个体中鉴定了SARS-CoV-2交叉反应性CD 4 + T 43细胞。此外，我们在轻度COVID-19患者中发现了可检测到的免疫44记忆，在45保护性适应性免疫的关键臂中恢复了几个月; CD 4 + T细胞和B细胞，46 CD 8 + T细胞的贡献最小。有趣的是，COVID-19患者的持续免疫记忆主要针对SARS-CoV-2的刺突糖蛋白。这项研究48提供了49个印度人群中既存在高强度免疫记忆又存在持久免疫记忆的证据。通过提供有关SARS-CoV-50 2细胞免疫反应的知识，我们的工作对开发和实施针对51 COVID-19的疫苗具有意义。52
38 Understanding the causes of the diverse outcome of COVID-19 pandemic in different 39 geographical locations is important for the worldwide vaccine implementation and pandemic 40 control responses. We analyzed 42 unexposed healthy donors and 28 mild COVID-19 subjects 41 up to 5 months from the recovery for SARS-CoV-2 specific immunological memory. Using 42 HLA class II predicted peptide megapools, we identified SARS-CoV-2 cross-reactive CD4+ T 43 cells in around 66% of the unexposed individuals. Moreover, we found detectable immune 44 memory in mild COVID-19 patients several months after recovery in the crucial arms of 45 protective adaptive immunity; CD4+ T cells and B cells, with a minimal contribution from 46 CD8+ T cells. Interestingly, the persistent immune memory in COVID-19 patients is 47 predominantly targeted towards the Spike glycoprotein of the SARS-CoV-2. This study 48 provides the evidence of both high magnitude pre-existing and persistent immune memory in 49 Indian population. By providing the knowledge on cellular immune responses to SARS-CoV-50 2, our work has implication for the development and implementation of vaccines against 51 COVID-19. 52